Treatment News : FDA Releases Updated Drug Interaction Information for Kaletra

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » February 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

February 4, 2013

FDA Releases Updated Drug Interaction Information for Kaletra

The U.S. Food and Drug Administration (FDA) has approved revisions to the label of the antiretroviral (ARV) Kaletra (lopinavir/ritonavir) in order to include new information on drug interactions. These include:

  • Anticoagulants: Xarelto (rivaroxaban). Kaletra raises Xarelto levels and can raise the risk of increased bleeding. Avoid combining the two drugs.
  • Anticonvulsants: Lamictal (lamotrigine) and valproate. Kaletra can lower their levels, potentially requiring a higher dose.
  • Corticosteroids (systemic): Uceris (Budesonide) and prednisone. Combining Kaletra with either drug can increase steroid concentrations and reduce cortisol concentrations in the blood.
  • Hepatitis C protease inhibitors: Victrelis (boceprevir) and Incivek (telaprevir). Use in combination with Kaletra is not recommended.
  • Inhaled or intranasal steroids: Uceris and similar brands. Use in combination is not recommended unless the potential benefit outweighs the risk of increased steroid concentrations and reduced serum cortisol concentrations.
  • PDE5 inhibitors: Stendra (avanafil). Do not combine the drugs, because a safe and effective dose of avanafil has not yet been established.
  • Studies show no clinically significant interaction between Kaletra and Isentress (raltegravir).
To see the FDA release, click here.

Search: U.S. Food and Drug Administration, FDA, HIV, Kaletra, drug interaction, lopinavir/ritonavir, Xarelto, rivaroxaban, Lamictal, lamotrigine, Uceris, Budesonide, Victrelis, boceprevir, Incivek, telaprevir, Stendra, avanafil, Isentress, raltegravir.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Hide comments

Previous Comments:


         


[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
Starting Treatment
Search for the Cure
POZ Stories
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar


    andais
    Red House
    West Virginia


    slimcuteguy
    Asheville
    North Carolina


    youngbloodlatino
    Columbia
    Maryland


    josebos
    KISSIMMEE
    Florida
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Can social media help stop HIV stigma?
Yes
No

Survey
Mind Matters

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.